Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OA-400
- Development stage
- Unknown
- Lead developer
- Oasis Pharmaceuticals
- Modality
- Peptides
01
Overview
OA-400 is a PAR2-targeting pepducin developed by Oasis Pharmaceuticals for the treatment of acute stroke. As a pepducin, it is a cell-penetrating lipopeptide designed to modulate G protein-coupled receptor (GPCR) signaling by interacting with the intracellular loops of the receptor. OA-400 specifically targets Protease-activated receptor 2 (PAR2), which plays a significant role in the inflammatory response and tissue damage following ischemic events. By modulating PAR2 signaling, OA-400 is intended to provide neuroprotection and improve outcomes in patients experiencing acute stroke. It is currently in clinical development.
02
Targets
PAR2 (Protease-activated receptor 2)
Beyond the preview
Go deeper on OA-400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OA-400.